This Article Full Text (PDF) All Versions of this Article: theoncologist.2008-0043v1 13/7/779    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adler, J. T. Articles by Sidhu, S. B. Search for Related Content PubMed PubMed Citation Articles by Adler, J. T. Articles by Sidhu, S. B.

Pheochromocytoma: Current Approaches and Future Directions

^aSection of Endocrine Surgery, Department of Surgery, University of Wisconsin, Madison, Wisconsin, USA; ^bEndocrine Surgical Unit, University of Sydney, ^cCancer Genetics, Kolling Institute of Medical Research, and ^dDepartment of Endocrinology, University of Sydney, Royal North Shore Hospital, New South Wales, Australia

Key Words. Pheochromocytoma • Management • Familial pheochromocytoma • Adrenal gland

Correspondence: Correspondence: Rebecca Sippel, M.D., H4/755 Clinical Science Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA. Telephone: 608-263-1387; Fax: 608-263-7652; e-mail: sippel{at}surgery.wisc.edu

Received February 21, 2008; accepted for publication June 3, 2008.

ABSTRACT

Pheochromocytomas are rare catecholamine-secreting tumors that arise from chromaffin tissue within the adrenal medulla and extra-adrenal sites. Because of the excess secretion of hormones, these tumors often cause debilitating symptoms and a poor quality of life. While medical management plays a significant role in the treatment of pheochromocytoma patients, surgical excision remains the only cure. Improved medical management and surgical techniques and an increased understanding of hereditary disease have improved the outcome of pheochromocytoma patients with benign disease; however, the outcome of patients with malignant disease remains poor. In this review, we discuss the presentation, diagnosis, management, and future directions in the management of this disease.

This article has been cited by other articles:

				P. J. Morrison and A. B. Atkinson Genetic Aspects of Familial Thyroid Cancer Oncologist, June 1, 2009; 14(6): 571 - 577. [Abstract] [Full Text] [PDF]